



## Claims

1. A compound of formula (I)



wherein

A is represented by

 group,  group, or  group,

$R^1$ is a $C_{1-4}$alkyl or halo-$C_{1-4}$alkyl group,

$R^2$ is a $C_{1-4}$alkyl, halo-$C_{1-4}$alkyl, $C_{1-4}$alkyl-$S(O)_2$-$C_{1-4}$alkyl, $C_{1-4}$alkoxy, $C_{3-7}$cycloalkyl, $C_{6-10}$aryl, optionally substituted $C_{3-10}$heterocycle, $C_{5-10}$heteroaryl, or $NR^3R^4$ group wherein $R^3$ and $R^4$ is each independently H, $C_{1-4}$alkyl, $C_{3-7}$cycloalkyl or $C_{3-10}$heterocycle group,

X is CH or N

and/or salts thereof and/or stereoisomers thereof and/or enantiomers thereof and/or racemates thereof and/or diastereomers thereof and/or solvates thereof and/or hydrates thereof and/or polymorphs thereof.

2. A compound according to claim 1, wherein $R^1$ is a $C_{1-2}$alkyl or halo-methyl group,

3. A compound according to any one of claims 1 to 2, wherein $R^1$ is a methyl, difluoromethyl or trifluoromethyl group.

4. A compound according to any one of claims 1 to 3, wherein $R^2$ is a $C_{1-4}$alkyl, halo-methyl, $C_{1-2}$alkyl-$S(O)_2CH_3$, $C_{1-4}$alkoxy, $C_{3-5}$cycloalkyl, phenyl, optionally substituted $C_{4-}$

$_6$heterocycle, $C_{5-6}$heteroaryl, or $NR^3R^4$ group wherein $R^3$ and $R^4$ is each independently H, $C_{1-2}$alkyl, $C_{3-5}$cycloalkyl or $C_{4-7}$heterocycle group.

5. A compound according to any one of claims 1 to 4, wherein $R^2$ is a methyl, fluoromethyl, trifluoromethyl, methylsulfonylmethane, *tert*-butoxy, $C_{3-4}$cycloalkyl, phenyl, optionally substituted $C_{4-6}$heterocycle comprising 1 or 2 ring heteroatoms independently selected from N, O and S, $C_{5-6}$heteroaryl comprising 1 or 2 ring heteroatoms independently selected from N, O and S, or $NR^3R^4$ group wherein $R^3$ and $R^4$ is each independently H, methyl, $C_{3-4}$cycloalkyl or $C_{4-6}$heterocycle group.

6. A compound according to any one of claims 1 to 5, wherein X is CH.

7. A compound according to any one of claims 1 to 5, wherein X is N.

8. A compound according to any one of claims 1 to 7 selected from the group consisting of

1-[6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl]ethanone,

*tert*-butyl 6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine-2-carboxylate,

*tert*-butyl 6-({5-methyl-3-[6-(trifluoromethyl)pyridin-3-yl]-1,2-oxazol-4-yl}methoxy)-1,2,3,4-tetrahydro-2,7-naphthyridine-2-carboxylate,

1-[6-({5-methyl-3-[6-(trifluoromethyl)pyridin-3-yl]-1,2-oxazol-4-yl}methoxy)-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl]ethanone,

2-methanesulfonyl-1-(6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)ethan-1-one,

2-cyclopropanecarbonyl-6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine,

6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-2-(pyridine-3-carbonyl)-1,2,3,4-tetrahydro-2,7-naphthyridine,

4-(6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine-2-carbonyl)-1lambda6-thiane-1,1-dione,

6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-2-(pyridine-4-carbonyl)-1,2,3,4-tetrahydro-2,7-naphthyridine,

6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-2-(oxane-4-carbonyl)-1,2,3,4-tetrahydro-2,7-naphthyridine,

2-cyclobutanecarbonyl-6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine,

6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-2-(oxolane-3-carbonyl)-1,2,3,4-tetrahydro-2,7-naphthyridine,

6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-2-(pyrrolidine-1-carbonyl)-1,2,3,4-tetrahydro-2,7-naphthyridine,

N,N-dimethyl-6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine-2-carboxamide,

1-methyl-4-(6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine-2-carbonyl)pyrrolidin-2-one,

4-(6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine-2-carbonyl)-1-(propan-2-yl)pyrrolidin-2-one,

2-(4-methyl-1,2-oxazole-5-carbonyl)-6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine,

2-(3-methyl-1,2-oxazole-5-carbonyl)-6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine,

6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-2-(oxane-3-carbonyl)-1,2,3,4-tetrahydro-2,7-naphthyridine,

1-methyl-5-(6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine-2-carbonyl)piperidin-2-one,

(5R)-1-methyl-5-(6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine-2-carbonyl)pyrrolidin-2-one,

(5S)-1-methyl-5-(6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine-2-carbonyl)pyrrolidin-2-one,

1-ethyl-4-(6-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine-2-carbonyl)pyrrolidin-2-one,

1-(3-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-5H,6H,7H,8H-pyrido[3,4-c]pyridazin-7-yl)ethan-1-one,

3-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-N-(oxan-4-yl)-5H,6H,7H,8H-pyrido[3,4-c]pyridazine-7-carboxamide,

4-(3-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-5H,6H,7H,8H-pyrido[3,4-c]pyridazine-7-carbonyl)morpholine,

2-methyl-5-[5-methyl-4-({[7-(oxane-4-carbonyl)-5H,6H,7H,8H-pyrido[3,4-c]pyridazin-3-yl]oxy}methyl)-1,2-oxazol-3-yl]pyridine,

5-{4-[({7-cyclopropanecarbonyl-5H,6H,7H,8H-pyrido[3,4-c]pyridazin-3-yl}oxy)methyl]-5-methyl-1,2-oxazol-3-yl}-2-methylpyridine,

1-(3-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-5H,6H,7H,8H-pyrido[3,4-c]pyridazin-7-yl)propan-1-one,

2-fluoro-1-(3-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-5H,6H,7H,8H-pyrido[3,4-c]pyridazin-7-yl)ethan-1-one,

2-methyl-1-(3-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-5H,6H,7H,8H-pyrido[3,4-c]pyridazin-7-yl)propan-1-one,

5-{4-[({7-cyclobutanecarbonyl-5H,6H,7H,8H-pyrido[3,4-c]pyridazin-3-yl}oxy)methyl]-5-methyl-1,2-oxazol-3-yl}-2-methylpyridine,

N-cyclopropyl-3-{[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy}-5H,6H,7H,8H-pyrido[3,4-c]pyridazine-7-carboxamide,

1-[3-({5-methyl-3-[6-(trifluoromethyl)pyridin-3-yl]-1,2-oxazol-4-yl}methoxy)-5H,6H,7H,8H-pyrido[3,4-c]pyridazin-7-yl]ethan-1-one,

2-methanesulfonyl-1-[6-({5-methyl-3-[6-(trifluoromethyl)pyridin-3-yl]-1,2-oxazol-4-yl}methoxy)-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl]ethan-1-one,

2,2,2-trifluoro-1-[6-({5-methyl-3-[6-(trifluoromethyl)pyridin-3-yl]-1,2-oxazol-4-yl}methoxy)-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl]ethan-1-one,

1-(6-{[4-methyl-1-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)ethan-1-one,

2-fluoro-1-(6-{[4-methyl-1-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)ethan-1-one,

2-methyl-1-(6-{[4-methyl-1-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)propan-1-one,

2,2-dimethyl-1-(6-{[4-methyl-1-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)propan-1-one,

3-methyl-1-(6-{[4-methyl-1-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)butan-1-one,

2-benzoyl-6-{[4-methyl-1-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine,

1-(6-{[4-methyl-1-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)propan-1-one,

2-cyclopropanecarbonyl-6-{[4-methyl-1-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine,

2-cyclobutanecarbonyl-6-{[4-methyl-1-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine,

6-{[4-methyl-1-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-2-(oxane-4-carbonyl)-1,2,3,4-tetrahydro-2,7-naphthyridine,

1-[6-({4-methyl-1-[6-(trifluoromethyl)pyridin-3-yl]-1H-1,2,3-triazol-5-yl}methoxy)-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl]ethan-1-one,

1-[6-({4-methyl-1-[6-(trifluoromethyl)pyridin-3-yl]-1H-1,2,3-triazol-5-yl}methoxy)-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl]propan-1-one,

2-fluoro-1-[6-({4-methyl-1-[6-(trifluoromethyl)pyridin-3-yl]-1H-1,2,3-triazol-5-yl}methoxy)-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl]ethan-1-one,

2-methyl-1-[6-({4-methyl-1-[6-(trifluoromethyl)pyridin-3-yl]-1H-1,2,3-triazol-5-yl}methoxy)-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl]propan-1-one,

2-cyclopropanecarbonyl-6-({4-methyl-1-[6-(trifluoromethyl)pyridin-3-yl]-1H-1,2,3-triazol-5-yl}methoxy)-1,2,3,4-tetrahydro-2,7-naphthyridine,

1-[3-{[4-methyl-1-(6-methylpyridin-3-yl)-1*H*-1,2,3-triazol-5-yl]methoxy}-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl]ethanone,

1-[3-({4-methyl-1-[6-(trifluoromethyl)pyridin-3-yl]-1*H*-1,2,3-triazol-5-yl}methoxy)-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl]ethanone,

1-[3-({1-[6-(difluoromethyl)pyridin-3-yl]-4-methyl-1*H*-1,2,3-triazol-5-yl}methoxy)-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl]ethanone,

1-[6-({1-[6-(difluoromethyl)pyridin-3-yl]-4-methyl-1*H*-1,2,3-triazol-5-yl}methoxy)-3,4 dihydro-2,7-naphthyridin-2(1*H*)-yl]ethanone,

1-[6-({1-[6-(difluoromethyl)pyridin-3-yl]-4-methyl-1*H*-1,2,3-triazol-5-yl}methoxy)-3,4 dihydro-2,7-naphthyridin-2(1*H*)-yl]propan-1-one,

2-fluoro-1-[6-({4-methyl-1-[6-(difluoromethyl)pyridin-3-yl]-1H-1,2,3-triazol-5-yl}methoxy)-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl]ethan-1-one,

2-cyclopropanecarbonyl-6-({4-methyl-1-[6-(difluoromethyl)pyridin-3-yl]-1*H*-1,2,3-triazol-5-yl}methoxy)-1,2,3,4-tetrahydro-2,7-naphthyridine,

2-methyl-1-[6-({4-methyl-1-[6-(difluoromethyl)pyridin-3-yl]-1*H*-1,2,3-triazol-5-yl}methoxy)-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl]propan-1-one,

1-(6-{[1-methyl-4-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)ethan-1-one,

2,2-dimethyl-1-(6-{[1-methyl-4-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)propan-1-one,

1-(6-{[1-methyl-4-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)propan-1-one,

2-methyl-1-(6-{[1-methyl-4-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)propan-1-one,

3-methyl-1-(6-{[1-methyl-4-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)butan-1-one,

2-cyclopropanecarbonyl-6-{[1-methyl-4-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine,

2-cyclobutanecarbonyl-6-{[1-methyl-4-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine,

2-benzoyl-6-{[1-methyl-4-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridine,

2-fluoro-1-(6-{[1-methyl-4-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl)ethan-1-one,

6-{[1-methyl-4-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-2-(oxane-4-carbonyl)-1,2,3,4-tetrahydro-2,7-naphthyridine, and

1-(6-{[1-methyl-4-(6-methylpyridin-3-yl)-1H-1,2,3-triazol-5-yl]methoxy}-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl]ethanone.

9. Use of a compound according to any one of claims 1 to 8, optionally in combination with one or more other active ingredients, for the manufacture of a medicament for the treatment or prevention of diseases related to the $GABA_A$ α5 receptor selected from the group consisting of neurodevelopmental disorders, neurodegenerative disorders, neurocognitive disorders, schizophrenia, mood disorders, pain disorders, substance-related and addictive disorders, and other diseases selected from the group consisting of attention deficit hyperactivity disorder and adult attention deficiency, other stress related conditions, stroke, neurofibromatosis type I, multiple sclerosis, acute meningitis, alcohol use disorder, fetal alcohol spectrum disorder, and bronchoconstrictive diseases.

10. The use according to claim 9, wherein the disease related to the $GABA_A$ α5 receptor is selected from the group consisting of autism spectrum disorder (ASD), Angelman syndrome, Fragile X disorder, Prader-Willi syndrome, Rett syndrome, Alzheimer's disease (AD), cognition deficiency disorders, memory deficits, age-associated memory impairment or cognitive decline, dementia, mild cognitive impairment (MCI), bipolar disorders, negative and/or cognitive symptoms associated with schizophrenia, epilepsy, post-traumatic stress disorder, amyotrophic lateral sclerosis.


11. A pharmaceutical composition comprising as active ingredient at least one compound according to any one of claims 1 to 8 and at least one physiologically or pharmaceutically acceptable excipient.

12. The pharmaceutical composition according to claim 11, wherein the composition further comprises one or more other active ingredients.

13. Us of the pharmaceutical composition according to claim 11 or 12 in the manufacture of a medicament for the treatment or prevention of diseases related to the $GABA_A$ α5 receptor selected from the group consisting of neurodevelopmental disorders, neurodegenerative disorders, neurocognitive disorders, schizophrenia, mood disorders, pain disorders, substance-related and addictive disorders, and other diseases selected from the group consisting of attention deficit hyperactivity disorder and adult attention deficiency, other stress related conditions, stroke, neurofibromatosis type I, multiple sclerosis, acute meningitis, alcohol use disorder, fetal alcohol spectrum disorder, and bronchoconstrictive diseases.

14. The use according to claim 13, wherein the disease related to the $GABA_A$ α5 receptor is selected from the group consisting of autism spectrum disorder (ASD), Angelman syndrome, Fragile X disorder, Prader-Willi syndrome, Rett syndrome, Alzheimer's disease (AD), cognition deficiency disorders, memory deficits, age-associated memory impairment or cognitive decline, dementia, mild cognitive impairment (MCI), bipolar disorders, negative and/or cognitive symptoms associated with schizophrenia, epilepsy, post-traumatic stress disorder, amyotrophic lateral sclerosis.

15. A compound of formula (V),




(V)


wherein

$R^2$ is $C_{1-4}$alkyl, halo-$C_{1-4}$alkyl, $C_{1-4}$alkyl-$S(O)_2$-$C_{1-4}$alkyl, $C_{1-4}$alkoxy, $C_{3-7}$cycloalkyl, $C_{6-10}$aryl, optionally substituted $C_{3-10}$heterocycle, $C_{5-10}$heteroaryl, or $NR^3R^4$ group wherein $R^3$ and $R^4$ is each independently H, $C_{1-4}$alkyl, $C_{3-7}$cycloalkyl or $C_{3-10}$heterocycle group,

X is CH or N,

with the proviso when X is N and $R^2$ is a methoxy, ethoxy group; when X is CH and $R^2$ is a methyl group; and when $R^2$ is a *tert*-butoxy group.

16. A compound of formula (VII),



(VII)


wherein

$R^2$ is $C_{1-4}$alkyl, halo-$C_{1-4}$alkyl, $C_{1-4}$alkyl-$S(O)_2$-$C_{1-4}$alkyl, $C_{1-4}$alkoxy, $C_{3-7}$cycloalkyl, $C_{6-10}$aryl, optionally substituted $C_{3-10}$heterocycle, $C_{5-10}$heteroaryl, or $NR^3R^4$ group wherein $R^3$ and $R^4$ is each independently H, $C_{1-4}$alkyl, $C_{3-7}$cycloalkyl or $C_{3-10}$heterocycle group,

X is CH or N,


with the proviso when X is CH and $R^2$ is a methyl, a 3-pyridinyl or a [6-methyl-4-[(1-methylcyclopropyl)amino]furo[2,3-*d*]pyrimidin-5-yl] group; when X is N and $R^2$ is a trifluoromethyl, a 5-methyl-3-isothiazolyl, or a 1-methyl-1H-pyrrol-2-yl group; and when $R^2$ is a *tert*-butoxy group.

17. A compound of formula formula (X) or (XI), wherein $R^1$ is a $C_{1-4}$alkyl or halo-$C_{1-4}$alkyl group



(X)

, or



(XI)

.

18. A compound selected from the group consisting of:

1-(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)-2-(methylsulfonyl)ethanone,

cyclopropyl(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)methanone,

(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)(pyridin-3-yl)methanone,

(1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)methanone,

(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)(pyridin-4-yl)methanone,

(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)(tetrahydro-2*H*-pyran-4-yl)methanone,

cyclobutyl(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)methanone,

(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)(tetrahydrofuran-3-yl)methanone,

4-[(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)carbonyl]-1-methylpyrrolidin-2-one,

4-[(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)carbonyl]-1-(propan-2-yl)pyrrolidin-2-one,

(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)(4-methyl-1,2-oxazol-5-yl)methanone,

(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)(3-methyl-1,2-oxazol-5-yl)methanone,

(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)(tetrahydro-2*H*-pyran-3-yl)methanone,

5-[(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)carbonyl]-1-methylpiperidin-2-one,

(5*R*)-5-[(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)carbonyl]-1-methylpyrrolidin-2-one,

(5*S*)-5-[(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)carbonyl]-1-methylpyrrolidin-2-one,

1-ethyl-4-[(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)carbonyl]pyrrolidin-2-one,

(6-hydroxy-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)(pyrrolidin-1-yl)methanone,

6-hydroxy-*N*,*N*-dimethyl-3,4-dihydro-2,7-naphthyridine-2(1*H*)-carboxamide,

1-(6-chloro-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)-2-fluoroethanone,

1-(6-chloro-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)-2-methylpropan-1-one,

1-(6-chloro-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)-2,2-dimethylpropan-1-one,

1-(6-chloro-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)-3-methylbutan-1-one,

(6-chloro-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)(phenyl)methanone,

1-(6-chloro-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)propan-1-one,

(6-chloro-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)(cyclopropyl)methanone,

(6-chloro-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)(cyclobutyl)methanone,

(6-chloro-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)(tetrahydro-2*H*-pyran-4-yl)methanone,

1-(3-chloro-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl)ethanone,

(3-chloro-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl)(morpholin-4-yl)methanone,

(3-chloro-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl)(tetrahydro-2*H*-pyran-4-yl)methanone,

(3-chloro-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl)(cyclopropyl)methanone,

1-(3-chloro-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl)propan-1-one,

1-(3-chloro-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl)-2-fluoroethanone,

1-(3-chloro-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl)-2-methylpropan-1-one,

(3-chloro-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl)(cyclobutyl)methanone,

1-(3-chloro-5,8-dihydropyrido[3,4-*c*]pyridazin-7(6*H*)-yl)-2-(methylsulfonyl)ethanone,

3-chloro-*N*-(tetrahydro-2*H*-pyran-4-yl)-5,8-dihydropyrido[3,4-*c*]pyridazine-7(6*H*)-carboxamide, and

3-chloro-*N*-cyclopropyl-5,8-dihydropyrido[3,4-*c*]pyridazine-7(6*H*)-carboxamide.

19. Use of the compound according to any one of claims 15 to 18 as an intermediate in the preparation of a compound of formula (I).